Cosciens Biopharma Inc.TSX: CSCI

Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD

· Issued by Cosciens Biopharma Inc.

Philip A. Theodore, Senior Vice President, ptheodore@aezsinc.comCopyright CNW Group 2015